Navana Pharmaceuticals PLC (DSE: NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT
45.50
+0.20 (0.44%)
At close: Jan 28, 2025
Navana Pharmaceuticals Revenue
Navana Pharmaceuticals had revenue of 2.14B BDT in the quarter ending September 30, 2024, with 31.01% growth. This brings the company's revenue in the last twelve months to 7.40B, up 23.37% year-over-year. In the fiscal year ending June 30, 2024, Navana Pharmaceuticals had annual revenue of 6.90B with 20.89% growth.
Revenue (ttm)
7.40B
Revenue Growth
+23.37%
P/S Ratio
0.66
Revenue / Employee
1.68M
Employees
4,408
Market Cap
4.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 6.90B | 1.19B | 20.89% |
Jun 30, 2023 | 5.71B | 947.45M | 19.91% |
Jun 30, 2022 | 4.76B | 1.15B | 31.95% |
Jun 30, 2021 | 3.61B | 457.57M | 14.53% |
Jun 30, 2020 | 3.15B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grameenphone | 161.36B |
Square Pharmaceuticals PLC. | 70.04B |
British American Tobacco Bangladesh Company | 93.12B |
Walton Hi-Tech Industries | 75.24B |
Robi Axiata PLC. | 101.06B |
Bangladesh Export Import Company | 25.18B |
BRAC Bank PLC. | 54.86B |
Berger Paints Bangladesh | 27.70B |